Japan first to approve Novartis' blockbuster hopeful Cosentyx; Bayer, Hospira win FDA nods;

> Japan has approved Novartis' ($NVS) Cosentyx as a treatment for psoriasis and psoriatic arthritis. Release

> The FDA has green-lighted Bayer's Gadavist injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age. Release

> The FDA has given Hospira ($HSP) a thumbs-up for its analgesic Dyloject injection, a treatment for pain management. Release

> Angelini will market Ariad's ($ARIA) Iclusig in Eastern Europe. Report

> Pfizer ($PFE) has granted Georgia State $850,000 to partner with Chinese health officials to expand tobacco control efforts in China's major cities. More

> The Asia-Pacific market for Type 2 diabetes treatments will hit $10.5 billion by 2020, GBI Research predicts. Release

And Finally... The Gates Foundation is using art to encourage vaccination. Story (sub. req.)

Suggested Articles

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.

Lions Health shared what worked, what campaigns they wish they had created and what they’ll take back home to talk about with their colleagues.

AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.